MedTrace Logo

A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

NCT03303313 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-10-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.

Conditions

  • Atypical Hemolytic Uremic Syndrome

Interventions

DRUG

Cemdisiran

Subcutaneous (sc) injection of Cemdisiran

Sponsors & Collaborators

Principal Investigators

  • Nader Najafian, MD · Alnylam Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-19
Primary Completion
2018-09-12
Completion
2018-09-12

Countries

  • Bosnia and Herzegovina
  • Canada
  • Estonia
  • Georgia
  • Latvia
  • Lithuania
  • Moldova
  • North Macedonia
  • Serbia
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03303313 on ClinicalTrials.gov